208 related articles for article (PubMed ID: 36167501)
1. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome.
Jonak CR; Pedapati EV; Schmitt LM; Assad SA; Sandhu MS; DeStefano L; Ethridge L; Razak KA; Sweeney JA; Binder DK; Erickson CA
J Neurodev Disord; 2022 Sep; 14(1):52. PubMed ID: 36167501
[TBL] [Abstract][Full Text] [Related]
2. GABA-B Agonist Baclofen Normalizes Auditory-Evoked Neural Oscillations and Behavioral Deficits in the
Sinclair D; Featherstone R; Naschek M; Nam J; Du A; Wright S; Pance K; Melnychenko O; Weger R; Akuzawa S; Matsumoto M; Siegel SJ
eNeuro; 2017; 4(1):. PubMed ID: 28451631
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic analysis of multielectrode array EEG biomarkers in developing and adult male Fmr1 KO mice.
Jonak CR; Assad SA; Garcia TA; Sandhu MS; Rumschlag JA; Razak KA; Binder DK
Neurobiol Dis; 2024 Jun; 195():106496. PubMed ID: 38582333
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical effect of baclofen on social behavior in the fragile X syndrome mouse model.
Zeidler S; Pop AS; Jaafar IA; de Boer H; Buijsen RAM; de Esch CEF; Nieuwenhuizen-Bakker I; Hukema RK; Willemsen R
Brain Behav; 2018 Jun; 8(6):e00991. PubMed ID: 29785777
[TBL] [Abstract][Full Text] [Related]
5. The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome.
Jonak CR; Sandhu MS; Assad SA; Barbosa JA; Makhija M; Binder DK
Neurotherapeutics; 2021 Apr; 18(2):1175-1187. PubMed ID: 33594533
[TBL] [Abstract][Full Text] [Related]
6. Translation-relevant EEG phenotypes in a mouse model of Fragile X Syndrome.
Lovelace JW; Ethell IM; Binder DK; Razak KA
Neurobiol Dis; 2018 Jul; 115():39-48. PubMed ID: 29605426
[TBL] [Abstract][Full Text] [Related]
7. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
[TBL] [Abstract][Full Text] [Related]
9. Multielectrode array analysis of EEG biomarkers in a mouse model of Fragile X Syndrome.
Jonak CR; Lovelace JW; Ethell IM; Razak KA; Binder DK
Neurobiol Dis; 2020 May; 138():104794. PubMed ID: 32036032
[TBL] [Abstract][Full Text] [Related]
10. Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome.
Kozono N; Okamura A; Honda S; Matsumoto M; Mihara T
Sci Rep; 2020 Nov; 10(1):18799. PubMed ID: 33139785
[TBL] [Abstract][Full Text] [Related]
11. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
Henderson C; Wijetunge L; Kinoshita MN; Shumway M; Hammond RS; Postma FR; Brynczka C; Rush R; Thomas A; Paylor R; Warren ST; Vanderklish PW; Kind PC; Carpenter RL; Bear MF; Healy AM
Sci Transl Med; 2012 Sep; 4(152):152ra128. PubMed ID: 22993295
[TBL] [Abstract][Full Text] [Related]
12. Sensory Processing Phenotypes in Fragile X Syndrome.
Rais M; Binder DK; Razak KA; Ethell IM
ASN Neuro; 2018; 10():1759091418801092. PubMed ID: 30231625
[TBL] [Abstract][Full Text] [Related]
13. FPT, a 2-Aminotetralin, Is a Potent Serotonin 5-HT
Saraf TS; McGlynn RP; Bhatavdekar OM; Booth RG; Canal CE
ACS Chem Neurosci; 2022 Dec; 13(24):3629-3640. PubMed ID: 36473166
[TBL] [Abstract][Full Text] [Related]
14. Increased aperiodic gamma power in young boys with Fragile X Syndrome is associated with better language ability.
Wilkinson CL; Nelson CA
Mol Autism; 2021 Feb; 12(1):17. PubMed ID: 33632320
[TBL] [Abstract][Full Text] [Related]
15. Reversal of ultrasonic vocalization deficits in a mouse model of Fragile X Syndrome with minocycline treatment or genetic reduction of MMP-9.
Toledo MA; Wen TH; Binder DK; Ethell IM; Razak KA
Behav Brain Res; 2019 Oct; 372():112068. PubMed ID: 31271818
[TBL] [Abstract][Full Text] [Related]
16. Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome.
Lovelace JW; Rais M; Palacios AR; Shuai XS; Bishay S; Popa O; Pirbhoy PS; Binder DK; Nelson DL; Ethell IM; Razak KA
Cereb Cortex; 2020 Mar; 30(3):969-988. PubMed ID: 31364704
[TBL] [Abstract][Full Text] [Related]
17. Developmental Changes in EEG Phenotypes in a Mouse Model of Fragile X Syndrome.
Wen TH; Lovelace JW; Ethell IM; Binder DK; Razak KA
Neuroscience; 2019 Feb; 398():126-143. PubMed ID: 30528856
[TBL] [Abstract][Full Text] [Related]
18. A sound-driven cortical phase-locking change in the Fmr1 KO mouse requires Fmr1 deletion in a subpopulation of brainstem neurons.
Holley AJ; Shedd A; Boggs A; Lovelace J; Erickson C; Gross C; Jankovic M; Razak K; Huber K; Gibson JR
Neurobiol Dis; 2022 Aug; 170():105767. PubMed ID: 35588990
[TBL] [Abstract][Full Text] [Related]
19. Abnormal development of auditory responses in the inferior colliculus of a mouse model of Fragile X Syndrome.
Nguyen AO; Binder DK; Ethell IM; Razak KA
J Neurophysiol; 2020 Jun; 123(6):2101-2121. PubMed ID: 32319849
[TBL] [Abstract][Full Text] [Related]
20. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome.
Rotschafer SE; Trujillo MS; Dansie LE; Ethell IM; Razak KA
Brain Res; 2012 Feb; 1439():7-14. PubMed ID: 22265702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
